These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 4671047)

  • 1. Immunochemotherapy of an established murine fibrosarcoma.
    Davis RC; Deckers PJ; Mannick JA
    Surg Forum; 1972; 23(0):125-7. PubMed ID: 4671047
    [No Abstract]   [Full Text] [Related]  

  • 2. Splenic influence on beta-hemolytic streptococci immunotherapy of a chemically induced murine fibrosarcoma.
    Yamagishi H; Pellis NR; Kahan BD
    Surg Forum; 1979; 30():125-7. PubMed ID: 395675
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.
    North RJ
    J Exp Med; 1982 Apr; 155(4):1063-74. PubMed ID: 6460831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cyclophosphamide on mice bearing methylcholanthrene-induced fibrosarcomas.
    Yu S; Lannin DR; Tsui-Collins AL; McKhann CF
    Cancer Res; 1980 Aug; 40(8 Pt 1):2756-61. PubMed ID: 7388826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cyclophosphamide inhibition of transplantable fibrosarcoma growth by augmentation of the host immune response.
    Ray PK; Raychaudhuri S
    J Natl Cancer Inst; 1981 Dec; 67(6):1341-5. PubMed ID: 6947115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide-induced changes in the cellular composition of a methylcholanthrene-induced tumor and their relation to bone marrow and blood leukocyte levels.
    Evans R; Madison LD; Eidlen DM
    Cancer Res; 1980 Feb; 40(2):395-402. PubMed ID: 7356522
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of a Moloney lymphoma with cyclophosphamide and H-2-incompatible spleen cells.
    Fefer A
    Cancer Res; 1973 Apr; 33(4):641-4. PubMed ID: 4696464
    [No Abstract]   [Full Text] [Related]  

  • 8. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
    Fujiwara H; Aoki H; Yoshioka T; Tomita S; Ikegami R; Hamaoka T
    J Immunol; 1984 Jul; 133(1):509-14. PubMed ID: 6233375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of host immunity in experimental radiotherapy].
    Tsuyuki K; Kubota T; Yamada Y; Hanatani Y; Nakada M; Ishibiki K; Abe O
    Nihon Gan Chiryo Gakkai Shi; 1983 Aug; 18(5):1108-15. PubMed ID: 6663165
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase. II. Intratumor injections of neuraminidase.
    Simmons RL; Rios A
    Surgery; 1972 Apr; 71(4):556-64. PubMed ID: 5021071
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful immunotherapy in a murine metastasizing fibrosarcoma model.
    Cortes R; Correa LA; Behbehani AI; Sonis ST; Wilson RE
    J Surg Oncol; 1984 Apr; 25(4):289-95. PubMed ID: 6717025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H-2 restriction of the T cell response to chemically induced tumors: evidence from F1 replaced by parent chimeras.
    Lannin DR; Yu S; McKhann CF
    J Immunol; 1982 Jan; 128(1):263-8. PubMed ID: 6459368
    [No Abstract]   [Full Text] [Related]  

  • 13. Active immunotherapy with Corynebacterium parvum and chemotherapy in murine fibrosarcomas.
    Currie GA
    Br Med J; 1970 Feb; 1(5695):541-4. PubMed ID: 5435189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.
    Plautz GE; Inoue M; Shu S
    Cell Immunol; 1996 Aug; 171(2):277-84. PubMed ID: 8806798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental immunotherapy of chemically induced fibrosarcomas in the mouse through active immunization].
    Borberg H
    Verh Dtsch Ges Inn Med; 1974; 80():1665-8. PubMed ID: 4454510
    [No Abstract]   [Full Text] [Related]  

  • 16. Experimental cancer immunotherapy using a neuraminidase-treated non-viable frozen tumor vaccine.
    Rios A; Simmons RL
    Surgery; 1974 Apr; 75(4):503-7. PubMed ID: 4840798
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of tumor size on concomitant tumor immunity.
    Deckers PJ; Davis RC; Parker GA; Mannick JA
    Cancer Res; 1973 Jan; 33(1):33-9. PubMed ID: 4682321
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.
    Rosenstein M; Eberlein TJ; Rosenberg SA
    J Immunol; 1984 Apr; 132(4):2117-22. PubMed ID: 6607955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
    Gomi K; Morimoto M; Nomoto K
    Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.